Keryx Biopharmaceuticals Inc (NASDAQ:KERX) Institutional Investors Sentiment Index Up in Q3 2017

January 21, 2018 - By Vivian Park

 Keryx Biopharmaceuticals Inc (NASDAQ:KERX) Institutional Investors Sentiment Index  Up in  Q3 2017

Sentiment for Keryx Biopharmaceuticals Inc (NASDAQ:KERX)

Keryx Biopharmaceuticals Inc (NASDAQ:KERX) institutional sentiment decreased to 1.5 in Q3 2017. Its down -0.47, from 1.97 in 2017Q2. The ratio worsened, as 57 hedge funds increased and opened new holdings, while 38 reduced and sold their positions in Keryx Biopharmaceuticals Inc. The hedge funds in our partner’s database now have: 75.60 million shares, down from 76.46 million shares in 2017Q2. Also, the number of hedge funds holding Keryx Biopharmaceuticals Inc in their top 10 holdings decreased from 3 to 1 for a decrease of 2. Sold All: 12 Reduced: 26 Increased: 43 New Position: 14.

Keryx Biopharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on providing medicines for patients with renal disease in the United States. The company has market cap of $579.42 million. It markets its lead product Auryxia , an orally available, absorbable, iron medicine for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis. It currently has negative earnings. The firm has licensing and collaboration agreements with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of Auryxia in Japan.

It closed at $4.86 lastly. It is down 13.56% since January 21, 2017 and is uptrending. It has underperformed by 3.14% the S&P500.

Analysts await Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) to report earnings on March, 7. They expect $-0.19 EPS, up 40.63 % or $0.13 from last year’s $-0.32 per share. After $-0.20 actual EPS reported by Keryx Biopharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -5.00 % EPS growth.

Consonance Capital Management Lp holds 4.11% of its portfolio in Keryx Biopharmaceuticals, Inc. for 5.23 million shares. Old West Investment Management Llc owns 710,912 shares or 2.65% of their US portfolio. Moreover, Baupost Group Llc Ma has 2.28% invested in the company for 25.79 million shares. The Massachusetts-based Abrams Capital Management L.P. has invested 1.58% in the stock. Knoll Capital Management Lp, a New York-based fund reported 200,000 shares.#img1#

Since January 1, 0001, it had 0 insider purchases, and 9 sales for $84,165 activity.

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Ratings Coverage

Ratings analysis reveals 40% of Keryx Biopharmaceuticals’s analysts are positive. Out of 15 Wall Street analysts rating Keryx Biopharmaceuticals, 6 give it “Buy”, 2 “Sell” rating, while 7 recommend “Hold”. The lowest target is $1.80 while the high is $18. The stock’s average target of $8.79 is 80.86% above today’s ($4.86) share price. KERX was included in 36 notes of analysts from July 23, 2015. On Friday, August 28 the stock rating was upgraded by Zacks to “Sell”. The rating was maintained by BTIG Research on Thursday, August 6 with “Sell”. The stock has “Hold” rating by Stifel Nicolaus on Wednesday, November 8. Cowen & Co maintained the shares of KERX in report on Friday, June 16 with “Hold” rating. Maxim Group maintained Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) rating on Thursday, July 27. Maxim Group has “Buy” rating and $900 target. The firm has “Buy” rating given on Tuesday, March 29 by Maxim Group. The stock has “Market Perform” rating by FBR Capital on Tuesday, August 2. The firm earned “Outperform” rating on Friday, February 26 by Raymond James. FBR Capital initiated Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) rating on Tuesday, August 11. FBR Capital has “Mkt Perform” rating and $10 target. The stock has “Hold” rating by Stifel Nicolaus on Tuesday, August 2.

Another recent and important Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) news was published by which published an article titled: “Keryx Biopharmaceuticals to Webcast its Presentation at JP Morgan’s 36th …” on December 22, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: